Heterogeneous diffuse large B-cell lymphoma: accurate diagnosis as a key to successful therapy. A review
- 作者: Babicheva L.1, Poddubnaya I.1
-
隶属关系:
- Russian Medical Academy of Continuous Professional Education
- 期: 卷 25, 编号 2 (2023)
- 页面: 168-177
- 栏目: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/132814
- DOI: https://doi.org/10.26442/18151434.2023.2.202237
- ID: 132814
如何引用文章
全文:
详细
Diffuse large B-cell lymphoma (DLBCL) is the most common variant of non-Hodgkin's lymphoma and accounts for about 1/3 of all non-Hodgkin's lymphomas in Western countries and about 40% of B-cell tumors worldwide. Correct diagnosis of clinically distinct subgroups of aggressive mature B-cell lymphomas is crucial for the choice of adequate treatment. Currently, the identification of DLBCL subtype depends on a combination of morphologic, immunophenotypic, and cytogenetic/molecular features. The classification covers the most common unspecified variant of DLBCL, also referred to as "not otherwise specified" (NOS), and a number of other rare forms. Over the past two decades, DLBCL NOS which accounts for more than 80% of all cases, has been the subject of a growing number of molecular studies that have identified prognostic factors that are being actively introduced into real-world clinical practice. Only the integration of morphological, immunohistochemical and molecular features of DLBCL will lead to the achievement of the long-term goal of curing the majority of patients with minimal or no toxic manifestations with the aid of personalized healthcare.
作者简介
Lali Babicheva
Russian Medical Academy of Continuous Professional Education
编辑信件的主要联系方式.
Email: lalibabicheva@mail.ru
ORCID iD: 0000-0001-8290-5564
Cand. Sci. (Med.)n Medical Academy
俄罗斯联邦, MoscowIrina Poddubnaya
Russian Medical Academy of Continuous Professional Education
Email: ivprectorat@inbox.ru
ORCID iD: 0000-0002-0995-1801
D. Sci. (Med.), Prof., Acad. RASn
俄罗斯联邦, Moscow参考
- Sarkozy C, Coiffier B. Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties. Clin Cancer Res. 2013;19(7):1660-9. DOI:1158/1078-0432.CCR-12-2837
- National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Available at: https://seer.cancer.gov/ Accessed: 18.01.2021.
- López-Guillermo A, Colomo L, Jiménez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol. 2005;23(12):2797-804. doi: 10.1200/JCO.2005.07.155
- Riedell PA, Smith SM. Double hit and double expressors in lymphoma: Definition and treatment. Cancer. 2018;124(24):4622-32. doi: 10.1002/cncr.31646
- Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. International Agency for Research on Cancer. Lyon, France, 2017; p. 2.
- Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. International Agency for Research on Cancer. Lyon, France, 2008.
- Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361-92. doi: 10.1182/blood.V84.5.1361.1361
- Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press. Lyon, France, 2001.
- Тумян Г.С. Новые возможности лечения диффузной В-крупноклеточной лимфомы. Клиническая онкогематология. 2022;15(3):213-31 [Tumyan GS. New Prospects for Treatment of Diffuse Large B-Cell Lymphoma. Clinical Oncohematology. 2022;15(3):213-31 (in Russian)].
- Поддубная И.В., Паровичникова Е.Н., Каприн А.Д., Ковригина А.М. Российские клинические рекомендации «Агрессивные нефолликулярные лимфомы – диффузная крупноклеточная В-клеточная лимфома, первичная медиастинальная В-клеточная лимфома, лимфома Беркитта» 2022 [Poddubnaya IV, Parovichnikova EN, Kaprin AD, Kovrigina AM. Rossiiskie klinicheskie rekomendatsii "Agressivnye nefollikuliarnye limfomy – diffuznaia krupnokletochnaia V-kletochnaia limfoma, pervichnaia mediastinal'naia V-kletochnaia limfoma, limfoma Berkitta" 2022 (in Russian)].
- Falini B, Martino G, Lazzi S. A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas. Leukemia. 2023;37:18-34. doi: 10.1038/s41375-022-01764-1
- Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720-48. doi: 10.1038/s41375-022-01620-2
- Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604-16. doi: 10.1002/ajh.25460
- Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74-87. doi: 10.1016/j.pathol.2017.09.006
- Horn H, Staiger AM, Vöhringer M, et al. Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations. Am J Surg Pathol. 2015;39(1):61-6. doi: 10.1097/PAS.0000000000000319
- Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood. 2010;116(23):4916-25. doi: 10.1182/blood-2010-03-276766
- Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-82. doi: 10.1182/blood-2003-05-1545
- Kaler AK, Shaila, Ashwini R, et al. Molecular profiling of large B-Cell lymphomas: A retrospective observational pilot study. J Precis Oncol. 2022;2(2):125-32. doi: 10.4103/jpo.jpo_19_22
- Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012;26(9):2103-13. doi: 10.1038/leu.2012.83
- Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452-9. doi: 10.1200/JCO.2011.41.0985
- Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-11. doi: 10.1038/35000501
- Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-47. doi: 10.1056/NEJMoa012914
- Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, et al. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol. 2009;22(8):1094-101. doi: 10.1038/modpathol.2009.73
- Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003;100(17):9991-6. doi: 10.1073/pnas.1732008100
- Choi WWL, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494-502. doi: 10.1158/1078-0432.CCR-09-0113
- de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications – a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25(7):805-12. doi: 10.1200/JCO.2006.09.4490
- Gutiérrez-García G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood. 2011;117(18):4836-43. doi: 10.1182/blood-2010-12-322362
- Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123(8):1214-7. doi: 10.1182/blood-2013-11-536433
- Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848-56. doi: 10.1200/JCO.2014.60.2383
- Jais JP, Molina TJ, Ruminy P, et al. Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay. Haematologica. 2017;102(10):e404-6. doi: 10.3324/haematol.2017.166827
- Gifford G, Gabrielli S, Gill A, et al. Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts. Br J Haematol. 2018;181(2):272-5. doi: 10.1111/bjh.14556
- Derenzini E, Mazzara S, Melle F, et al. A three-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma. Haematologica. 2021;106(9):2405-16. doi: 10.3324/haematol.2019.236455
- Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460-7. doi: 10.1200/JCO.2011.41.4342
- Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021-31. doi: 10.1182/blood-2012-10-460063
- Rosenwald A, Bens S, Advani R, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2019;37(35):3359-68. doi: 10.1200/JCO.19.00743
- Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354-61. doi: 10.1182/blood-2014-05-578963
- Scott DW, King RL, Staiger AM, et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. 2018;131(18):2060-4. doi: 10.1182/blood-2017-12-820605
- Kurz KS, Ott M, Kalmbach S, et al. Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms – Updated Classification and New Concepts. Cancers (Basel). 2023;15(8):2285. doi: 10.3390/cancers15082285
- Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-90. doi: 10.1038/s41591-018-0016-8
- Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396-407. doi: 10.1056/NEJMoa1801445
- Pileri SA, Tripodo C, Melle F, et al. Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas. Cells. 2021;10(3):675. doi: 10.3390/cells10030675
- Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128(21):2489-96. doi: 10.1182/blood-2016-05-718528
- Fuchs M, Goergen H, Kobe C, et al. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. J Clin Oncol. 2019;37(31):2835-45. doi: 10.1200/JCO.19.00964
- Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118(1):37-43. doi: 10.1182/blood-2010-12-327767
- Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36(28):2845-53. doi: 10.1200/JCO.2018.78.5246
- The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987-94. doi: 10.1056/NEJM199309303291402
- Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041-8. doi: 10.1182/blood.2019002729
- Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150-6. doi: 10.1200/JCO.2015.65.6520
- Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016;127(18):2182-8. doi: 10.1182/blood-2015-10-676700
- Orellana-Noia VM, Reed DR, Sen JM, et al. CNS prophylaxis during front-line therapy in aggressive non-Hodgkin lymphomas: real-world outcomes and practice patterns from 19 US academic institutions. Blood. 2020;136(Suppl. 1):27-8. doi: 10.1182/blood-2020-134798
- Di Napoli A, Remotti D, Agostinelli C, et al. A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era: selecting cases, matching clinical benefit: A position paper from the Italian Group of Haematopathology (G.I.E.). Virchows Arch. 2019;475(4):513-8. doi: 10.1007/s00428-019-02637-2.